Eur J Heart Fail:射血分数保留的心衰患者运动时的心率和搏出量变化

2021-03-11 Nebula MedSci原创

射血分数保留的心力衰竭(HFpEF)的一个标志是不同程度的运动能力受损

射血分数保留的心力衰竭(HFpEF)的一个标志是不同程度的运动能力受损。运动能力的主要决定因素是心输出量(CO),HFpEF患者的运动能力受损主要是在体力运动时不能根据外周需求增加CO。但是,目前HFpEF患者的CO构成(心率×每搏输出量)与运动量之间的关系鲜有报道。

本研究旨在探究HFpEF患者对运动的心率和每搏量反应是否存在异质性,并描述与这些反应差异相关的可能临床表型。

采用了两个HFpEF的前瞻性试验(n=108)和一项健康受试者(n=42)在运动过程中有创血流动力学测量的数据。用回归模型分析中心血流动力学反应的差异。

心率和搏出量变化的相关性

分析结果显示,39-56%的HFpEF患者和3-56%的健康受试者存在变时性功能不全,但部分HFpEF患者(n=47,44%)的心率增加与健康对照组相似。HFpEF患者的每搏输出量指数(SVI)增加较少(HFpEF:+4±10ml/m2,健康受试者:+24±12ml/m,p<0.0001),实际上,28%的患者在运动高峰时的SVI下降。

心指数的变化

在HFpEF患者中,安静时较高的BMI和较低的SVI与运动时较少的心率增加有关,而较高的静息心率和ACE抑制剂/血管紧张素受体阻滞剂(ARB)的使用与较多的SVI增加有关。

总之,HFpEF患者运动时的血流动力学反应具有很明显的异质性,高达56%的患者存在变时性功能不全,28%的患者的SVI增加受损。这表明血流动力学运动试验可能有助于确定哪些HFpEF患者可能受益于针对每搏输出量和变时性反应的干预。

注释:

心脏变时性功能:正常窦房结在神经、体液等因素调节下,根据机体不同状况,在较大范围内改变心率的快慢以满足机体供血、代谢的需要,这种功能称为心脏变时性功能。

心脏变时性功能不全:窦房结对运动或代谢等病理生理变化丧失了应用的正常心率反应,即心率增快未达到一定程度,称为心脏变时性功能不全。

原始出处:

Wolsk Emil,Kaye David M,Komtebedde Jan et al. Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. Eur J Heart Fail, 2021, 10.1002/ejhf.2146

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746319, encodeId=66431e46319c3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Tue Sep 21 01:31:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961149, encodeId=a59e96114944, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6c68a372854f41b5adb49f135b753d9d/1a1eb9a2fcda4ae6a56dc5fb7bacdb20.jpg, createdBy=47355464648, createdName=鳌拜拜, createdTime=Wed Apr 28 10:19:53 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959622, encodeId=831895962287, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Thu Apr 22 23:29:08 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357663, encodeId=67fa135e66370, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373511, encodeId=3e8a13e351123, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563421, encodeId=0bed15634216c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746319, encodeId=66431e46319c3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Tue Sep 21 01:31:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961149, encodeId=a59e96114944, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6c68a372854f41b5adb49f135b753d9d/1a1eb9a2fcda4ae6a56dc5fb7bacdb20.jpg, createdBy=47355464648, createdName=鳌拜拜, createdTime=Wed Apr 28 10:19:53 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959622, encodeId=831895962287, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Thu Apr 22 23:29:08 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357663, encodeId=67fa135e66370, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373511, encodeId=3e8a13e351123, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563421, encodeId=0bed15634216c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-04-28 鳌拜拜

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1746319, encodeId=66431e46319c3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Tue Sep 21 01:31:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961149, encodeId=a59e96114944, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6c68a372854f41b5adb49f135b753d9d/1a1eb9a2fcda4ae6a56dc5fb7bacdb20.jpg, createdBy=47355464648, createdName=鳌拜拜, createdTime=Wed Apr 28 10:19:53 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959622, encodeId=831895962287, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Thu Apr 22 23:29:08 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357663, encodeId=67fa135e66370, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373511, encodeId=3e8a13e351123, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563421, encodeId=0bed15634216c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-04-22 Doctoryangbai

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1746319, encodeId=66431e46319c3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Tue Sep 21 01:31:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961149, encodeId=a59e96114944, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6c68a372854f41b5adb49f135b753d9d/1a1eb9a2fcda4ae6a56dc5fb7bacdb20.jpg, createdBy=47355464648, createdName=鳌拜拜, createdTime=Wed Apr 28 10:19:53 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959622, encodeId=831895962287, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Thu Apr 22 23:29:08 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357663, encodeId=67fa135e66370, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373511, encodeId=3e8a13e351123, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563421, encodeId=0bed15634216c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-03-13 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746319, encodeId=66431e46319c3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Tue Sep 21 01:31:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961149, encodeId=a59e96114944, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6c68a372854f41b5adb49f135b753d9d/1a1eb9a2fcda4ae6a56dc5fb7bacdb20.jpg, createdBy=47355464648, createdName=鳌拜拜, createdTime=Wed Apr 28 10:19:53 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959622, encodeId=831895962287, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Thu Apr 22 23:29:08 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357663, encodeId=67fa135e66370, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373511, encodeId=3e8a13e351123, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563421, encodeId=0bed15634216c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746319, encodeId=66431e46319c3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Tue Sep 21 01:31:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961149, encodeId=a59e96114944, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6c68a372854f41b5adb49f135b753d9d/1a1eb9a2fcda4ae6a56dc5fb7bacdb20.jpg, createdBy=47355464648, createdName=鳌拜拜, createdTime=Wed Apr 28 10:19:53 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959622, encodeId=831895962287, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Thu Apr 22 23:29:08 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357663, encodeId=67fa135e66370, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373511, encodeId=3e8a13e351123, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563421, encodeId=0bed15634216c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Mar 13 01:31:51 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-03-13 slcumt

相关资讯

JACC-Heart Failure:营养不良与HFpEF患者心血管风险增加相关

营养不良与各种疾病的不良预后相关,然而,营养不良对射血分数保留的心力衰竭(HFpEF)患者预后的影响尚不清楚。JACC: Heart Failure发表的一项研究旨在探讨营养不良与HFpEF患者不良心血管(CV)事件的关系。

Circulation:研究发现重度肥胖会降低心衰患者的心肌收缩力

来自约翰霍普金斯医学院的最新研究发现,对于患有这种心衰的患者,重度肥胖会使心肌收缩减弱。

JACC:年轻HFpEF患者更常见于肥胖男性,且猝死率高

虽然,射血分数保留的心力衰竭(HFpEF)被认为是老年人的疾病,但年轻患者也可出现这种综合症。JACC发表的一项研究探讨了HFpEF患者的年龄、临床特征和预后的关系。

JAHA:伴有顽固性高血压的射血分数正常的心力衰竭患者使用螺内酯的疗效分析

螺内酯可能是治疗伴有顽固性高血压的HFpEF患者的有效药物。

Circulation:射血分数正常的心衰患者血管紧张素-脑啡肽酶抑制的疗效

与采用缬沙坦治疗相比,沙库必曲/缬沙坦治疗降低了HFpEF患者发生肾脏事件的风险,并延缓了eGFR的下降速度。

J Am Coll Cardiol:螺内酯相关的肾功能恶化对HFpEF患者预后的影响

研究目的是评估WRF、螺内酯治疗与HFpEF患者临床结局之间的关系。